As for patients with GHD and concurrent diseases with intra-portal hypoinsulinemia (e.g., T1D and inflammatory diseases), higher GH doses are required to normalize IGF-I levels, which has cost implications. The gene discussed is IGF1; the disease is type 1 diabetes mellitus.